Company news

Mirum Pharmaceuticals, Inc. news in 2024

Mirum Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting

November 13, 2024

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

November 11, 2024

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

November 3, 2024

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

October 30, 2024

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis

October 9, 2024

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

August 6, 2024

Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024

July 30, 2024

Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

July 24, 2024

Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC

July 7, 2024

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

June 27, 2024

Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

June 16, 2024

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024

June 15, 2024

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress

June 5, 2024

Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

May 30, 2024

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress

May 28, 2024

Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting

May 17, 2024

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024

Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

May 6, 2024

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

May 6, 2024

Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

April 30, 2024

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

April 1, 2024

Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

March 12, 2024

Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI

February 28, 2024

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

February 27, 2024

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024

February 20, 2024

Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer

January 15, 2024

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates

January 7, 2024

Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Calls in 2024

Decks in 2024